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ESSENTIALS 
• Not all patients carry the same risk of developing a post-thrombotic syndrome 
• Prediction models could estimate the risk of post thrombotic syndrome after a 
deep vein thrombosis 
• Our prediction model is based on six predictors  
• Patients at high risk of developing post thrombotic syndrome are accurately 
identified 
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ABSTRACT 
Background:  
Not all patients carry the same risk of developing a post-thrombotic syndrome (PTS) 
after a deep vein thrombosis (DVT). We sought to derive a clinical prediction model 
to estimate the risk of PTS within 24 months of a DVT. 
Methods: 
Our derivation sample included 276 patients with a first acute symptomatic lower 
limb DVT enrolled in a prospective cohort. We derived our prediction rule using 
regression analysis, with the occurrence of PTS within 24 months of a DVT based on 
the Villalta score as outcome, and 12 candidate variables as predictors. We used 
bootstrapping methods for internal validation. 
Results:  
Overall, 161 patients (58.3%) developed a PTS within 24 months of a DVT. Our 
prediction rule was based on 6 predictors (age ≥75 years, lower extremity artery 
disease, prior varicose vein surgery, multilevel thrombosis, concomitant 
antiplatelet/NSAID therapy, and the number of leg symptoms and signs). Overall, 
16.3%, 30.8%, and 52.9% of patients were classified as low (score 0-3), moderate 
(score 4-5), and high-risk (score ≥6), for developing a PTS. Within 24 months of the 
index DVT, 24.4% of the patients in the low-risk category developed a PTS, 38.8% in 
the moderate, and 80.1% in the high-risk category. The prediction model showed 
good discriminatory power (AUC 0.79; 95% confidence interval 0.74-0.84). Internal 
validation showed similar results. 
Conclusions:  
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This easy to use clinical prediction rule accurately identifies patients with DVT who 
are at high risk of developing PTS within 24 months who could potentially benefit 
from special educational or therapeutic measures to limit the risk of PTS.  
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INTRODUCTION 
Deep vein thrombosis (DVT) is a very common disease, with an annual 
incidence of 95 cases per 100,000 population [1]. The post-thrombotic syndrome 
(PTS), defined as chronic venous symptoms and/or signs secondary to DVT, is the 
most common long-term complication of DVT and occurs in 20% to 50% of patients 
within 2 years [2]. Patients with PTS often suffer from pain, heaviness, swelling, and 
cramping in the limb. These symptoms are aggravated by standing or walking and 
tend to improve with rest and recumbence [3, 4]. About 2 to 30% of patients with 
symptomatic DVT develop severe PTS that is characterized by the presence of 
painful venous ulcers [2]. Therefore, PTS has a measurable adverse impact on 
morbidity and quality of life [5-7]. The socioeconomic impact of PTS is significant 
with an estimated annual direct cost of US $200 million[8] and an annual loss of 2 
million work days in the U.S [9]. Because existing treatment options for  PTS are 
limited, prevention is a key measure to reduce the impact of this illness on morbidity, 
quality of life, and costs of care. 
Growing evidence suggests that not all patients carry the same risk of 
developing PTS [10]. Several clinical factors apparent at time of DVT diagnosis, such 
as extensive proximal DVT, previous ipsilateral DVT, older age, body mass index 
>25 kg/m2, vein insufficiency, inflammation and fibrinolysis, and residual vein 
obstruction appear to increase the risk of PTS [11-14]. D-dimer levels and 
suboptimal quality of anticoagulant therapy are other risk factors for PTS 
development [15-17]. To date, good anticoagulation quality is the only evidence-
based modifiable risk factor for PTS prevention [13, 14, 18]. 
At present, no method accurately estimating individual risk for PTS 
development following a DVT is available. Therefore, an easy-to-use clinical 
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prognostic model that accurately risk-stratifies patients with DVT would be very 
useful for medical decision-making. Patients at high-risk of developing PTS could 
benefit from special educational measures to achieve optimal quality of oral 
anticoagulant therapy, thus reducing the morbidity and costs related to this 
complication. Such patients could also be included in interventional research 
protocols designed to test whether prolonged anticoagulation course or treatment 
with direct oral anticoagulants could lower the incidence of PTS, or alternatively, 
whether they may benefit from early venous recanalization or elastic stocking 
compression. Our study objective was to derive a clinical prediction model for 
prognosis to estimate the risk of PTS within 24 months of an index DVT. 
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METHODS 
Study design, setting and participants 
We used data prospectively collected from the SWIss venous 
Thromboembolism COhort (SWITCO65+) to develop our score. SWITCO65+ is a 
prospective multicenter cohort study that enrolled and followed up 1003 in- and 
outpatients aged ≥65 years with acute symptomatic, objectively confirmed deep vein 
thrombosis (DVT) and/or pulmonary embolism (PE) from all five university and four 
high-volume non-university hospitals in Switzerland between September 2009 and 
December 2013. Exclusion criteria were inability to provide informed consent (i.e., 
severe dementia), conditions incompatible with follow-up (i.e., terminal illness), 
insufficient German or French-speaking ability, thrombosis at a different site than 
lower limb, catheter-related thrombosis, or previous enrolment in the cohort. A 
detailed description of the study methods has been published previously [19]. The 
study was approved by the Institutional Review Board at each participating center. 
Because our aim was to derive a clinical score identifying patients at high-risk of PTS 
within 2 years after DVT, our analysis was restricted to patients with a first lower limb 
DVT episode to avoid the inclusion of patients with pre-existing PTS. The 
development of the prediction rule was guided by internationally recognized 
methodological standards [20-26]. 
 
Selection of predictor variables 
In a first step, we identified clinical risk factors associated with the occurrence 
of PTS following an episode of acute symptomatic DVT, from the literature and we 
searched for these variables in the SWITCO65+ database [10, 12-14, 27]. To 
increase clinical applicability and acceptability of the score, we favored explicit and 
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clinically plausible predictor variables that are easily available in a medical office 
setting. We did not consider potential predictors that are not routinely available 
(biomarkers of inflammation and fibrinolysis, or thrombophilic risk factors) [13, 14, 
27]. We chose prior varicose vein surgery instead of primary vein insufficiency 
because the latter needs a confirmation by duplex ultrasound and was not available 
in the Switco65+ database. We did not consider potential predictors of PTS that were 
not available in the Switco65+ database (smoking during pregnancy, asymptomatic 
DVT, ipsilateral DVT recurrence) [14]. Since patients with iliofemoral DVT are a 
subset of patients with proximal DVT, and thus highly correlated to PTS, this variable 
was omitted from the model. Because our goal was to develop a score with a large 
applicability, we also considered common comorbid conditions, i.e. cancer related-
VTE and lower extremity artery disease (LEAD), the latter sharing some clinical 
signs and symptoms with PTS. Symptomatic LEAD affects about 6% of patients 
aged >65 [28, 29]. The incomplete resolution of leg symptoms and signs one month 
after DVT was previously shown to predict PTS risk.[10] As this variable was not 
available in the SWITCO65+ database, we included leg symptoms and signs 
assessed at baseline as a proxy variable in the model. 
Our final selection of candidate variables comprised 12 baseline predictors:  
age (≥75 years), gender (female), type of DVT (provoked versus unprovoked VTE, or 
cancer-related VTE), extent of thrombosis burden (concomitant PE, multilevel 
thrombosis, proximal DVT), increased body mass index (≥30 kg/m2), prior varicose 
vein surgery, concomitant antiplatelet or NSAID therapy, LEAD  and the magnitude 
of leg signs and symptoms at baseline [10, 12-14, 27]. 
Trained study nurses who prospectively collected baseline demographic 
information, comorbid conditions (such as LEAD, prior varicose vein surgery and 
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concomitant antiplatelet or NSAID therapy) and DVT-related treatment using patient 
interviews and hospital chart review, obtained all baseline clinical variables used to 
derive our prediction rule. At the time of index DVT, study nurses also assessed the 
presence of DVT-related signs and symptoms (pain, cramps, heaviness, pruritus, 
paresthesia, edema, skin induration, hyperpigmentation, venous ectasia, redness, 
pain during calf compression) using standardized forms. Of note, duration of 
anticoagulant treatment, as well as elastic compression stockings, were prescribed 
at the treating physician’s discretion.  
 
Study outcome 
The study outcome used to derive our prediction model was the occurrence of 
PTS within 24 months from index event based on the Villalta score.[30] The Villalta 
score is a clinical tool used to diagnose and categorize the severity of PTS.  Five 
patient-rated symptoms (pain, cramps, heaviness, pruritus, and paresthesia) and six 
clinician-rated clinical signs (edema, redness, skin induration, hyperpigmentation, 
venous ectasia, and pain on calf compression) are graded depending on their 
presence and degree of severity from 0 points (absent) to 3 points (severe). 
Presence of PTS was defined as a Villalta score of ≥5 [31]. PTS severity is 
categorized as: mild (5 to 9 score points), moderate (10 to 14 score points), and 
severe (>14 score points or presence of a venous ulcer). The Villalta score is well 
validated, has good to excellent inter-observer reliability, and is responsive to clinical 
change [32, 33]. 
Patient follow-up included one telephone interview and two face-to-face 
evaluations during the first year of study participation, then semi-annual contacts, 
alternating between face-to-face evaluations (clinic visits or home visits in house-
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bound patients) and telephone calls, as well as periodic reviews of the patient’s 
hospital chart. Study nurses performed a standardized assessment of the PTS at 3, 
12, and 24 months using the Villalta scale. Managing physicians were blinded to the 
Villalta results. Study nurses collected INR values obtained during the 
anticoagulation period. 
During follow-up, trained vascular specialists assessed residual vein 
thrombosis within three months of the first DVT event. Residual vein thrombosis was 
defined as presence, in at least one affected vein, of a residual thrombus with a 
surface greater than 40% of diameter of the vein [34]. 
 
Statistical analyses 
Derivation of the prediction model 
The initial cohort comprised 1003 consenting patients with VTE. We excluded 
557 patients with PE only, 109 with a history of prior DVT, and 16 with venous ulcer 
at baseline, leaving 321 patients with a first DVT. After the exclusion of another 45 
patients (38 without PTS assessment during follow-up, 4 denying use of data, and 7 
early consent withdrawals), our final study sample comprised 276 patients with a first 
acute DVT. We compared baseline characteristics of patients with and without PTS 
within 24 months using the chi-square test for categorical variables and the non-
parametric Wilcoxon rank sum test for continuous variables. We assessed 
associations between preselected risk factors and PTS within 24 months as outcome 
variable using logistic regression. 
We used backward selection to identify risk factors, removing variables with a 
p-value of >0.2. We evaluated model calibration, i.e. how accurately the model-
based expected number of events matches the observed number of PTS in each risk 
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group, using the Gronnesby and Borgan goodness-of-fit test for survival data.[35] 
We assigned one score point to each binary variable and each item of the 
continuous variable that were retained in the model and assessed the discrimination 
of the summed score, i.e. its ability to discriminate between patients who develop a 
PTS and those who do not, using the area under the receiver operating 
characteristic (ROC) curve. Additionally, we assessed the calibration of the score 
using the Brier score. We then classified patients into three categories of increasing 
risk (low, moderate, high) and calculated the observed risk of PTS at 3, 12, and 24 
months for each risk category. We chose a cut-off point to identify patients who are 
at high- vs. lower risk of PTS at 24 months. While there is no universally accepted 
cut-off point for defining a high risk of PTS, we considered a 80% probability of 
developing a PTS as high and a 20% probability as low. Finally, we assessed the 
predictive accuracy for the high risk category (high versus moderate and low risk) 
calculating the sensitivity, specificity, and the positive and negative predictive value. 
Because the Villalta scale also classifies patients with PTS into severity categories, 
we assessed how good the score identifies severe PTS (Villalta score >14). 
 
Internal validation of the prediction model 
We used bootstrapping methods to assess the internal validity of the derived 
risk score. All steps from prediction modeling to score derivation were performed in 
each bootstrap cycle. Bootstrap sampling was performed 1000 times from the 
original sample, sampling the same number of patients as in the original sample with 
replacement. In each bootstrap sample, we derived a prediction model. Based on 
this model, the risk score was generated in the respective bootstrap sample as well 
as in the original sample. Performance measures, such as the AUC and the Brier 
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score, were calculated from both samples. The difference in the performance 
measure between the two samples was subtracted from the original measure, 
yielding a bootstrap-corrected performance measure [36]. The 95% confidence 
intervals (CI) for the bootstrapped area under the ROC curve were derived using the 
percentile method. Additionally, we evaluated how often variables were selected in 
the bootstrap samples. All analyses were done using Stata 14 (Stata Corporation, 
College Station, Texas). 
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RESULTS 
Patient characteristics 
Analyzed patients had a median age of 74 years, 46% were women, 32% had 
concomitant PE, and 18% presented an isolated distal DVT as the initial VTE event. 
The majority (60%) of DVT events was unprovoked and 17% of DVTs were cancer-
related. Analyzed patients were similar to those excluded because of prior DVT in 
terms of age, gender, and comorbid conditions. 
Overall, 161 patients (58.3%) developed a PTS within 24 months based on 
the Villalta score. Patients who developed a PTS were older and sicker than those 
without PTS (Table 1). Elastic compression stockings were prescribed in three 
quarter of patients after the acute DVT episode; however, the proportion of patients 
with PTS within 24 months did not vary according to compression stockings 
prescription (Table 1). Among patients with  proximal DVT and an assessable leg 
vein ultrasonography performed at three months, 61% (n=171) had residual vein 
thrombosis. Residual vein thrombosis was more frequent in patients who developed 
a PTS at 24 months compared to those who did not, but this difference was not 
statistically significant (64% versus 54%, P=0.223). The median duration of initial 
anticoagulation was 6.3 months (interquartile range [IQR]: 3.3-19.7). Overall, 
patients spent 66.6% of time within the therapeutic range (IQR: 48.0-81.1) and 16.2 
% of time (IQR 5.6-34.6) below the therapeutic range. The percentage of time within 
the therapeutic range did not vary significantly in patients with PTS compared to 
those without (65.3% versus 69.0%; p=0.123). 
 
Derivation of the Prediction model 
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Patient factors retained in the model after backward selection were age ≥75 
years, presence of LEAD, prior varicose vein surgery, multilevel thrombosis, 
concomitant antiplatelet or NSAID therapy, and number of leg symptoms and signs. 
The latter included pain, cramps, heaviness, pruritus, paresthesia, edema, skin 
induration, hyperpigmentation, venous ectasia, redness, and pain during calf 
compression.  Number of leg symptoms and signs was used as a continuous 
variable in the model to ensure a ratio of predictors to outcomes of around 1:10 to 
avoid model overfitting. Patients with PTS had a higher prevalence of these leg 
symptoms and signs than patients without PTS (Table 1). The scoring system shown 
in Table 2 was used to assign points to each patient. Model calibration by the 
goodness-of-fit test showed a p-value of 0.12. 
Overall, 16.3%, 30.8%, and 52.9% of patients were classified as low (score 0-
3), moderate (score 4-5), and high-risk for PTS (score ≥6), respectively. Within 24 
months of an index lower limb acute symptomatic proximal DVT, 24.4% of patients in 
the low-risk category developed a PTS, 38.8% in the moderate, and 80.1% in the 
high-risk category. 
The selected model had a good discriminatory power for PTS within 24 
months (AUC 0.79; 95% confidence interval [CI] 0.74-0.84), as well as for severe 
PTS (Villalta >14) within 24 months (AUC 0.82; 95% CI 0.67-0.96). Using a cut-off  of 
≥6 points to identify patients at high vs. lower risk of PTS at 24 months,  sensitivity, 
specificity, and positive and negative predictive value of the score was 72.7%, 
74.8%, 80.1% and 66.2% respectively (Table 3). The resulting score discriminated 
well between patients with and without PTS after 3, 12, and 24 months (Table 4).  
 
Internal validation of the prediction rule 
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In the bootstrap validation, the area under the ROC curve of the score was 
only slightly lower than that in the derivation cohort after 24 months (0.77; 95% CI 
0.72-0.83, Table 4), indicating only little overfitting in the original prediction model. 
The variables most often selected in the bootstrap samples (>50%) were the same 
as the 6 predictors initially selected in the derivation cohort. 
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DISCUSSION 
Using high-quality data from a prospective cohort study, we derived an easy-
to-use clinical score to predict the risk of developing a PTS within 24 months after an 
acute symptomatic proximal DVT. Six clinical predictors accurately identified patients 
at high risk of PTS. Internal validation confirmed the good discriminatory power of 
the score. To our knowledge, no other tool predicting the risk of PTS development 
after a first acute symptomatic proximal DVT exists to date. 
To increase clinical applicability and acceptability of the score, we used only 
variables that are easily available in a medical office setting. Four predictors 
variables, i.e. older age, prior varicose vein surgery, multilevel thrombosis, and leg 
symptoms and signs are established predictors of PTS [11-13].  In our prediction 
model, concomitant NSAID or antiplatelet therapy at time of DVT was a predictor of 
PTS, which is in accordance with a previous study by Galanaud et al [27]. NSAIDs 
and antiplatelet therapy may be markers of comorbidity, such as cardiovascular or 
chronic orthopedic diseases, which both may present with leg symptoms mimicking 
PTS. One variable of the PTS, LEAD, was not previously identified as a predictor of 
PTS. Some of the symptoms of LEAD, such as cramps/pain, or skin changes may 
also be captured by the Villalta score and thus may generate a spurious association 
between LEAD and PTS. 
The rule has important clinical and research implications. Given that no 
treatment for PTS exists, prevention remains a key measure. Evidence suggests that 
good anticoagulation quality effectively prevents PTS [14, 18]. In a prospective 
study, patients with a first DVT who spent more than 50% of their time below an INR 
level of 2.0 were almost three times more likely to develop a PTS [18]. Another 
recent multinational multicenter study confirmed this finding in 349 patients followed 
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during six months after a first unprovoked DVT. During the first 3 months of therapy, 
the odds ratio for developing PTS if a patient had subtherapeutic anticoagulation 
during more than 20% of time was 1.84 (95% CI 1.13-3.01).[17] 
Currently, European and American guidelines recommend providing 
anticoagulation of appropriate intensity and duration for treatment of initial DVT to 
decrease the risk of recurrent DVT and consequent PTS [14, 37]. The association 
between subtherapeutic anticoagulation with vitamin K antagonist (VKA) and 
subsequent PTS should encourage physicians to perform frequent and regular INR 
monitoring of patients receiving vitamin K antagonists, especially in the first months 
of treatment [14]. The net benefit of strategies aiming at improving the quality of 
long-term anticoagulation in patients at high risk of PT development might not only 
lower the PTS incidence but also have the potential to improve the quality of life after 
a first DVT event [5]. 
A recent large multicenter, placebo-controlled trial, enrolling 809 patients after 
a first episode of symptomatic proximal DVT assessed the effect of elastic 
compression stockings in preventing PTS [38]. In this trial, the use of compression 
stocking did not reduce PTS. Based on this recent evidence, guidelines suggest not 
to routinely use compression stockings to prevent PTS in patients with acute 
DVT.[14, 39] Because the application of elastic compression stockings remains 
reasonable to reduce symptomatic swelling in patients after a DVT, [37] physicians 
could restrict the prescription of elastic compression stockings to patients with a high 
risk of PTS according to the rule. 
Finally, whether potential treatments, such as the use of direct oral 
anticoagulants, catheter-directed thrombolysis [14, 39], immediate mobilization after 
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DVT [40], exercise after DVT [41] and weight reduction [27] could reduce the risk of 
PTS in high-risk patients based on the score should be prospectively evaluated. 
 
Limitations 
The score has potential limitations. First, it was derived in patients aged 65 or 
older, which may limit the generalizability of its use. However, 55% of VTE occurs in 
patients older than 65 years old [42]. Moreover, our derivation cohort included a 
broad population of in and out patients with provoked and unprovoked DVT from 
university and non-university hospitals in Switzerland, thus increasing generalizability 
of the score [22]. Second, because direct oral anticoagulants were not authorized for 
treatment of acute DVT in Switzerland during the patient enrollment period, our score 
was developed in a sample of patients treated with VKA. Whether the score 
accurately predicts the risk of PTS in patients treated with direct oral anticoagulants, 
must be further studied.  
In conclusion, we successfully derived and internally validated a practical 
score that accurately classifies patients with a first acute symptomatic DVT into three 
categories of increasing PTS risk. High-risk patients based on the score have an 
80.1% probability to develop PTS and may be candidates for educational and 
therapeutic strategies aiming at decreasing the risk of developing PTS. Further 
validation of the score is mandatory before its implementation into clinical practice. 
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Table 1. Baseline characteristics by incidence of post-thrombotic 
syndrome within 24 months 
 
 All PTS 
within 24 
months 
No PTS 
within 24 
months 
 
  n (%) or median (IQ-range)  p value 
Total N N = 276 N = 161 N = 115   
Patient age 74.0 (68.3; 80.0) 75.0 (70.0; 80.5) 71.0 (68.0; 77.0) 0.001 
Age ≥75 128 (46) 88 (55) 40 (35) 0.001 
Gender (female) 128 (46) 76 (47) 52 (45) 0.744 
Type/severity of DVT     
Provoked DVT† 86 (31) 48 (30) 38 (33) 0.568 
Concomitant PE 88 (32) 43 (27) 45 (39) 0.029 
Proximal DVT 205 (74) 128 (80) 77 (67) 0.019 
Distal DVT only 49 (18) 26 (16) 23 (20) 0.409 
Highest extent    0.328 
inferior vena cava  6  (2) 4  (2) 2  (2) 0.828 
iliac vein 39 (14) 30 (19) 9  (8) 0.038 
common femoral vein 46 (17) 27 (17) 19 (17) 0.552 
superficial femoral vein 63 (23) 36 (22) 27 (23) 0.297 
popliteal vein 51 (18) 31 (19) 20 (17) 0.778 
Iliofemoral DVT‡ 151 (55) 95 (59) 56 (49) 0.090 
Multilevel thrombosis§ 179 (65) 112 (70) 67 (58) 0.052 
Comorbid condition     
LEAD 22  (8) 18 (11) 4  (3) 0.020 
BMI >30 57 (21) 40 (25) 17 (15) 0.042 
Prior varicose vein surgery 33 (12) 27 (17) 6  (5) 0.004 
DVT-related treatment     
Concomittant 
antiplatelet/NSAID therapy 
93 (34) 63 (39) 30 (26) 0.024 
Prescription of compression 
stockings 
201 (73) 117 (73) 84 (73) 0.945 
Initial VKA therapy 240 (87) 143 (89) 97 (84) 0.277 
Type of initial parenteral AC    0.600 
 LMWH 131 (47) 82 (51) 49 (43) 0.172 
 UFH 81 (29) 44 (27) 37 (32) 0.384 
 Fondaparinux 51 (18) 28 (17) 23 (20) 0.582 
 None 13  (5) 7  (4) 6  (5) 0.737 
DVT signs/symptoms at 
baseline 
    
Pain 148 (54) 92 (57) 56 (49) 0.165 
Cramps 96 (35) 67 (42) 29 (25) 0.005 
Heaviness 105 (38) 75 (47) 30 (26) 0.001 
Pruritus 49 (18) 37 (23) 12 (10) 0.007 
Paresthesia 65 (24) 46 (29) 19 (17) 0.020 
Edema 180 (65) 119 (74) 61 (53) <0.001 
Skin induration 62 (22) 51 (32) 11 (10) <0.001 
Hyperpigmentation 89 (32) 62 (39) 27 (23) 0.008 
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Table 1 (continued)     
 All PTS 
within 24 
months 
No PTS 
within 24 
months 
 
  n (%) or median (IQ-range) p value 
Venous ectasia 171 (62) 122 (76) 49 (43) <0.001 
Redness 99 (36) 69 (43) 30 (26) 0.004 
Pain during calf compression 122 (44) 81 (50) 41 (36) 0.016 
Number of leg signs and 
symptoms 
4.0 (3.0; 6.0) 5.0 (4.0; 6.0) 3.0 (2.0; 5.0) <0.001 
Abbreviation: PTS: post-thrombotic syndrome ; IQ : interquartile ; DVT: deep vein thrombosis; BMI : 
body mass index ; NSAID : non steroidal anti-inflammatory drug; VKA: vitamin K antagonist, LEAD: 
lower extremity arterial disease 
 
*Provoked index DVT: Transient risk factor (immobilization, major surgery or current estrogen therapy 
in the last 3 months). 
†Proximal DVT with or without concomitant PE 
§Distal DVT only (no concomitant proximal DVT nor PE) 
‡Iliofemoral DVT: Thrombosis in iliac vein, and/or common femoral vein and/or superficial femoral 
vein. 
**Multilevel thrombosis: Thrombosis in at least two veins. 
††Active cancer: Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, and/or 
palliative care during the last 3 months. 
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Table 2: Post-thrombotic syndrome risk at 24 months in patients with proximal 
deep vein thrombosis  
 
Post-thrombotic syndrome risk score 
 
Predictors OR 
(95% CI) 
β-Coefficient  
(95% CI) 
Points 
assigned 
Age ≥75 years 1.61 (0.91 to 2.86) 0.48 (-0.10-1.05) +1 
Concomitant antiplatelet/NSAID 
therapy 
1.98 (1.05 to 3.71) 0.68 (0.05-1.31) +1 
Multilevel thrombosis 1.66 (0.93 to 2.98) 0.51 (-0.07-1.09) +1 
LEAD 2.50 (0.73 to 8.60) 0.91 (-0.32-2.15) +1 
Prior varicose vein surgery 2.82 (1.04 to 7.65) 1.04 (0.04-2.03) +1  
Number of leg signs and 
symptoms* 
1.65 (1.40 to 1.95) 0.50 (0.34-0.67) +1 (for each) 
  AUC (95%CI)  
Model  0.79 (0.74-0.85)  
Abbreviations: OR: odds ratio; CI : confidence interval ; NSAID : non steroidal anti-inflammatory drug, LEAD: 
lower extremity arterial disease ; AUC : area under the ROC curve. 
 
* pain, cramps, heaviness, pruritus, paresthesia, edema, skin induration, hyperpigmentation, venous ectasia, 
redness, pain during calf compression. 
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Table 3: Predictive accuracy for risk category ≥6 points (high versus 
medium/low risk) 
 
PTS Sensitivity %  
(95% CI) 
Specificity %  
(95% CI) 
PPV %  
(95% CI) 
NPV %  
(95% CI) 
Within 3 months 76.9  
(68.1 - 83.8) 
62.5  
(55.0 - 69.5) 
56.8  
(48.7 - 64.6) 
80.8  
(73.2 - 86.6) 
Within 12 
months 
72.9  
(65.0 - 79.5) 
67.6  
(59.4 - 74.9) 
69.9  
(62.0 - 76.7) 
70.8  
(62.4 - 77.9) 
Within 24 
months 
72.7  
(65.3 - 79.0) 
74.8  
(66.1 - 81.8) 
80.1  
(72.9 - 85.8) 
66.2  
(57.7 - 73.7) 
Abbreviation: PTS : post-thrombotic syndrome ; PPV : positive predictive value ; NPV : negative predictive value ; 
CI : confidence interval 
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Table 4: Performance of the post-thrombotic syndrome risk score prediction 
over time 
 
Pronostic Model Derivation sample Internal validation  
 
PTS 
AUC  
(95%-CI) 
Brier 
score 
AUC  
(95%-CI) 
Brier score 
Within 3 months 0.76  
(0.71 to 0.82) 
0.19 0.75  
(0.70 to 0.81) 
0.19 
Within 12 months 0.75 
(0.69 to 0.80) 
0.20 0.73  
(0.68 to 0.79) 
0.21 
Within 24 months 0.79  
(0.74 to 0.84) 
0.18 0.77  
(0.72 to 0.83) 
0.19 
 Abbreviation: PTS: post-thrombotic syndrome  
 
